Activating the Immune System to Treat Multiple Myeloma

Sagar Lonial, MD

Chief Medical Officer, Winship Cancer Institute of Emory University

Chair, Dept. of Hematology and Medical Oncology, Emory School of Medicine

Faculty/Faculty Disclosure

Dr. Lonial reports that he is a compensated consultant for Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Click here to read the supplement

Sagar Lonial, MD

Chief Medical Officer, Winship Cancer Institute of Emory University

Chair, Dept. of Hematology and Medical Oncology, Emory School of Medicine

Faculty/Faculty Disclosure

Dr. Lonial reports that he is a compensated consultant for Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Click here to read the supplement

Sagar Lonial, MD

Chief Medical Officer, Winship Cancer Institute of Emory University

Chair, Dept. of Hematology and Medical Oncology, Emory School of Medicine

Faculty/Faculty Disclosure

Dr. Lonial reports that he is a compensated consultant for Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Click here to read the supplement